Zentalis Pharmaceuticals, Inc. Operating Income Loss

• Zentalis Pharmaceuticals, Inc. showed an increase of +20.1% in Operating Income Loss from 2024 to 2025.
• This data is from Zentalis Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), Zentalis Pharmaceuticals, Inc.'s Operating Income Loss has declined by 226.2%.
• Historical annual values: Fiscal year 2025: -$152.81 million | Fiscal year 2024: -$191.19 million | Fiscal year 2023: -$299.51 million | Fiscal year 2022: -$227.29 million | Fiscal year 2021: -$216.54 million | Fiscal year 2020: -$118.79 million | Fiscal year 2019: -$46.85 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026